Heart Rhythm O2 (Feb 2021)

Catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation

  • Daniel J. Friedman, MD,
  • Michael E. Field, MD, FHRS,
  • Motiur Rahman, PhD,
  • Laura Goldstein, MPH,
  • Qun Sha, MD,
  • M. Sidharth, BTech,
  • Rahul Khanna, BPharm, MBA, PhD,
  • Jonathan P. Piccini, MD, MHS, FHRS

Journal volume & issue
Vol. 2, no. 1
pp. 28 – 36

Abstract

Read online

Background: Ablation reduces atrial fibrillation (AF) burden and improves health-related quality of life. The relationship between ablation, healthcare utilization, and AF type (paroxysmal AF [PAF] vs persistent AF [PsAF]) remains unclear. Objective: To compare changes in AF-related healthcare utilization and costs from preablation to postablation among patients with PAF and PsAF. Methods: Patients (2794 PAF, 1909 PsAF) undergoing ablation (2016–2018) were identified using the Optum database. Outcomes included inpatient admissions, emergency department (ED) visits, office visits, cardioversion, and antiarrhythmic drug (AAD) use. Costs (2018 US$) and outcomes were compared for the year before/after ablation using the McNemar test and Wilcoxon signed rank test. Results: Compared to PAF patients, PsAF patients were older (68.6 ± 9.0 years vs 67.4 ± 9.9 years, P < .0001), were less commonly female (36.3% vs 44.1%, P < .0001), and more commonly had a CHA2DS2-VASc ≥ 3(71.2% vs 62.7%, P < .0001). The 12-month postablation costs were lower for AF-specific inpatient admissions (PAF -28%, PsAF -33%), ED visits (PAF -76%, PsAF -70%), AAD prescription fills (PAF -25%, PsAF -7%), and cardioversions (PAF -59%, PsAF -55%) as compared to 12 months before ablation. Although these reductions were observed for both PAF and PsAF patients, absolute costs remained higher for PsAF. Total AF costs were higher during the 1 year after ablation vs before ablation (PAF: 11%, P < .0001; PsAF: 10%, P < .0001) owing to repeat ablation. However, in the 18-month follow-up analysis, postablation costs were overall reduced (PAF: 35%, P < .0001; PsAF: 34%, P < .0001), despite including costs from repeat ablation. Conclusion: Significant reductions in healthcare utilization and costs were observed among PAF and PsAF patients undergoing ablation. These data suggest a strategy of earlier ablation may reduce long-term healthcare utilization and costs.

Keywords